Oppenheimer Holdings reaffirmed its 'outperform' rating, and TD Cowen reaffirmed a 'buy' rating for Praxis Precision Medicines.
1 report, 1 independent
Updated Jun 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Oppenheimer Holdings reaffirmed its 'outperform' rating, and TD Cowen reaffirmed a 'buy' rating for Praxis Precision Medicines.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Oppenheimer Holdings
investment bank and investment firm
Nothing else this week.
-
TD Cowen
American investment bank
Related events
- TD Cowen reaffirmed a buy rating on Tectonic Therapeutic (TECX) on October 13, 2026.
- TD Cowen reiterated a buy rating on MBX Biosciences shares, and Citigroup restated an outperform rating on the company.
- Bio-Techne shares traded on Nasdaq, and TD Cowen reiterated a Buy rating with a $65 price target.
- TD Cowen reaffirmed a buy rating on Alaska Airlines.
- TD Cowen issued a buy rating and price target for Dexcom on October 9, 2026.